8-K filing — ONCOLYTICS BIOTECH INC (ONCY)

Oncolytics Biotech Anticipates Reporting Final Results From Group 4 Of Its GOBLET Phase 1/2 Trial In Q4 For Pelareorep With Atezolizumab To Treat Squamous Cell Anal Carcinoma; To Receive Payment Under Grant From Pancreatic Cancer Action Network This Quarter

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced an update regarding the status of its GOBLET Phase

Oncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044

New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near termThree patent applications are pending, including two method

Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences